Targeting SWI/SNF mutant cancers with tyrosine kinase inhibitor therapy.
a Division of Cancer Biology , The Institute of Cancer Research , London , UK.
Paul H
PH
Huang
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002868:Chromosomal Proteins, Non-Histone / Q000235:genetics*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D014157:Transcription Factors / Q000235:genetics*
D000970:Antineoplastic Agents; D002868:Chromosomal Proteins, Non-Histone; D047428:Protein Kinase Inhibitors; C445179:SWI-SNF-B chromatin-remodeling complex; D014157:Transcription Factors
SMARCB1; SWI/SNF; cancer; receptor tyrosine kinase; signal transduction; tyrosine kinase inhibitor